Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$275.13 USD

275.13
1,143,135

+4.68 (1.73%)

Updated May 31, 2024 04:00 PM ET

After-Market: $275.22 +0.09 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

United Therapeutics Corporation [UTHR]

Reports for Purchase

Showing records 301 - 320 ( 589 total )

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 301

06/01/2017

Industry Report

Pages: 50

June and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 302

05/23/2017

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 303

05/02/2017

Daily Note

Pages: 46

May and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 304

04/27/2017

Company Report

Pages: 8

Q1 Financials--Top-line Miss and Bottom-line Beat: Return to Revenue Growth Anticipated in 2017; Reiterate OUTPERFORM but Reducing PT to $213

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 305

04/25/2017

Daily Note

Pages: 4

Post-IPR Update: Thinking Through a Possible Appeal Process and Implications of New Patents

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 306

04/21/2017

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 307

04/17/2017

Company Report

Pages: 10

Statistical Deep Dive Into the Upcoming FREEDOM-EV Interim Look

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 308

04/04/2017

Daily Note

Pages: 6

Negative IPR for ''393 Patent Expected and Appealable--RemoSync Has Another Delay but RemoPro is on the Way; Reiterate OUTPERFORM and $229 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 309

04/04/2017

Daily Note

Pages: 46

April and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 310

04/03/2017

Daily Note

Pages: 6

Negative IPR for ''393 Patent Expected and Appealable--RemoSync Has Another Delay but RemoPro is on the Way; Reiterate OUTPERFORM and $229 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 311

03/28/2017

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 312

03/08/2017

Daily Note

Pages: 42

March and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 313

02/28/2017

Daily Note

Pages: 5

IP Update: Thinking Through the Various Litigation Scenarios in Coming Months

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 314

02/27/2017

Company Report

Pages: 10

Q4/FY16 Financials Choppy; However, New Product Approval and Phase 3 Data Readout on the Horizon; Reiterate OUTPERFORM and $229 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 315

02/27/2017

Company Report

Pages: 10

Q4/FY16 Financials Choppy; However, New Product Approval and Phase 3 Data Readout on the Horizon; Reiterate OUTPERFORM and $229 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 316

02/27/2017

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 317

02/23/2017

Company Report

Pages: 6

Our View on the Strategic Shift Towards Expensive BD in 2017: Takeover Thesis Not in Play

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 318

02/20/2017

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 319

02/06/2017

Daily Note

Pages: 45

February and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 320

01/31/2017

Daily Note

Pages: 3

Competitive Update: Selexipag Pharmacovigilance in France; We Expect Quick Resolution

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party